# Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT01733238** · PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 13 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin's

## Interventions

- **DRUG:** PNT2258

## Key facts

- **NCT ID:** NCT01733238
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733238, "Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01733238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*